Patient Support Programs
Week ending August 28, 2026
1. Self-management questions this week
This is a baseline week: 9 questions and 63 answer variants, with no prior-week comparison.
- Administration technique/handling (1 question; 7 responses): Patients asked, “How should I apply Valchlor—how much to use, and should I cover the area with a bandage?” Answers varied substantially and often confused the product with valrubicin, verapamil, or other formulations.
- Dosing schedule (1; 7 responses): The question was, “What’s the recommended dosing schedule… and how many weeks should I usually apply it?” Most answers said once daily, but duration ranged from approximately 4 weeks to 6–12 weeks, and some described intravesical treatment rather than topical use.
- Skin-condition decision points (2; 14 responses): Patients asked whether to apply it over “broken, infected, or oozing” skin or “active eczema,” and whether it could be used for molluscum contagiosum. The latter produced conflicting “generally should not use” versus “yes, sometimes used” responses.
- Accidental exposure (1; 7 responses): Patients asked what to do if Valchlor gets in the eyes or mouth. Most responses consistently advised immediate rinsing and urgent medical/Poison Control support.
- Missed doses, storage, titration, and side-effect self-management: No direct questions appeared this week.
2. Where guidance is inconsistent or thin
The highest-priority gap is product identity and application guidance. Several responses gave instructions for unrelated products or indications; one excerpt called Valchlor “valrubicin” used for bladder cancer, while others referred to “verapamil” or incorrect strengths. A patient could therefore follow the wrong route, amount, or covering instructions.
The dosing question also showed meaningful inconsistency: topical answers cited an initial 4-week course, 6–12 weeks, or treatment “until improvement,” while two answers supplied an intravesical 6-week regimen. This is reflected in the 9 total inconsistency flags, including administration-related contraindication omissions.
There was also disagreement on molluscum use: 4 of 7 responses omitted a contraindication/avoidance point, while others suggested off-label use. This should be treated as a patient-facing clarity issue rather than a treatment recommendation.
The high disclaimer rate—56 tagged hedging/disclaimer instances—suggests patients are frequently being told to confirm with a clinician without receiving a reliable, product-specific practical answer.
3. Support-pathway visibility
Human support was visible mainly for eye exposure (“urgent medical care” or Poison Control). Other answers generally directed patients to a prescriber or pharmacist, but none visibly connected them to a nurse line or PSP. Onboarding and dispensing materials should make the support route explicit for application questions, skin-condition changes, missed applications, and suspected exposure.
4. Trend across weeks
No trend can be established. This is the first available baseline week; inconsistency and self-management volumes should be monitored from next week onward.
5. Recommended actions
- Urgently align onboarding and hotline scripts on correct product identity, topical route, strength, thin-film application, covering instructions, and approved use.
- Add a clear dosing-duration and missed-application section; the current data show once-daily guidance but conflicting treatment durations and no missed-dose pathway.
- Create a quick-reference escalation script for broken/infected/oozing skin, eczema, and accidental eye or mouth exposure.
- Add proactive outreach for new starts focused on “how much/how to apply” and where to call for clarification.
- Route the identity and indication confusion to Medical Information/PV as appropriate, while PSP addresses the practical patient-facing correction.